Akeso’s Ivonescimab Outshines Pembrolizumab on Overall Survival in Phase 3 HARMONi-2 Trial
China’s Akeso has reported another major clinical milestone for ivonescimab (AK112), its first-in-class PD-1/VEGF bispecific antibody, announcing that the drug demonstrated a statistically significant and clinically meaningful overall survival (OS)…
HUTCHMED Licenses KRAS-EGFR ATTC HMPL-A830 to GSK in Deal Worth Up to $1.295 Billion
China-based biopharmaceutical company HUTCHMED has entered into an exclusive global licensing and development agreement with GSK for HMPL-A830, a potentially first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), in a transaction that could…
Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
Simnova Raises Nearly RMB 400 Million in Series B Financing to Advance CAR-NK and In Vivo CAR-T Platforms
Shanghai-based cell therapy developer Simnova has completed a nearly RMB 400 million (approximately US$55 million) Series B financing round, providing fresh capital to advance its lead off-the-shelf CAR-NK program SNC103 and its emerging in vivo CAR-T…
Chia Tai Tianqing Pharma (CTTQ)
Innovating for Life, Creating Greater Health Value
CStone Pharmaceuticals
Building Globally Competitive Innovative Medicines
China’s Personalized mRNA Cancer Vaccine Race Accelerates After Moderna and Merck’s Phase 3 Melanoma Success
The personalized cancer vaccine field has reached a major inflection point. Moderna and Merck announced on August 19, 2026 that their Phase 3 INTerpath-001 trial of intismeran autogene (V940/mRNA-4157) plus KEYTRUDA (pembrolizumab) met both its primary…
HUTCHMED’s Fanregratinib Wins China NMPA Approval for FGFR2+ Intrahepatic Cholangiocarcinoma (ICC)
HUTCHMED has secured conditional approval from China’s National Medical Products Administration (NMPA) for fanregratinib (HMPL-453), providing a new targeted treatment option for patients with FGFR2-altered intrahepatic cholangiocarcinoma (ICC). The NMPA…
TYK Medicines Wins China Approval for Asandeutertinib in EGFR-Mutant NSCLC With Brain Metastases
China’s NMPA has granted conditional approval to asandeutertinib (TY-9591), TYK Medicines’ brain-penetrant, deuterated EGFR inhibitor, for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer with central nervous…